Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma DOI Open Access
Marwa Tantawy, Taimour Langaee, Daqing Wang

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7795 - 7795

Published: July 16, 2024

This study investigates the association between circulating microRNA (miRNA) expression and cardiovascular adverse events (CVAE) in multiple myeloma (MM) patients treated with a carfilzomib (CFZ)-based regimen. A cohort of 60 MM from Prospective Observation Cardiac Safety Proteasome Inhibitor (PROTECT) was analyzed. Among these, 31 (51.6%) developed CVAE post-CFZ treatment. The Taqman OpenArray Human panels were used for miRNA profiling. We identified 13 differentially expressed miRNAs at baseline, higher expressions miR-125a-5p, miR-15a-5p, miR-18a-3p, miR-152-3p lower miR-140-3p who later compared to those free CVAE, adjusting age, gender, race, B-type natriuretic peptide levels. also three miRNAs, including miR-150-5p, that without post-treatment. Additionally, five responded differently CFZ treatment vs. non-CVAE patients, significantly elevated post-treatment miR-598, miR-152, miR-21, miR-323a patients. Pathway enrichment analysis highlighted involvement these diseases vascular processes. These findings suggest specific could serve as predictive biomarkers provide insights into underlying mechanisms CFZ-CVAE. Further investigation is warranted before can be applied clinical settings.

Language: Английский

Cardioprotective potential of oleuropein, hydroxytyrosol, oleocanthal and their combination: Unravelling complementary effects on acute myocardial infarction and metabolic syndrome DOI Creative Commons

Andriana Christodoulou,

Panagiota Nikolaou,

Lydia Symeonidi

et al.

Redox Biology, Journal Year: 2024, Volume and Issue: 76, P. 103311 - 103311

Published: Aug. 14, 2024

Clinical studies have previously established the role of olive products in cardiovascular disease (CVD) prevention, whilst identification responsible constituents for beneficial effects is still pending. We sought to assess and compare cardioprotective potential oleuropein (OL), hydroxytyrosol (HT), oleocanthal (OC) oleanolic Acid (OA), regarding Ischemia/Reperfusion Injury (IRI) CVD risk factors alleviation. The scope study was design a potent safe combinatorial therapy high-cardiovascular-risk patients on bench-to-bedside approach. evaluated IRI-limiting 6-weeks treatment with OL, HT, OC or OA at nutritional doses, healthy metabolic syndrome (MS)-burdened mice. Three regimens were designed mixture preponderant benefits (OL-HT-OC, Combo 2), including infarct sparing antiglycemic potency, compared isolated compounds, further investigated its anti-atherosclerotic effects. In vivo experiments revealed that combination regimen 2 presented most favorable limiting size hyperglycemia, which selected be clinical setting Chronic Coronary Artery Syndrome (CCAS) patients. Cardiac function, inflammation markers oxidative stress assessed baseline after 4 weeks OL-HT-OC supplement study. found significantly reduced Controls. OL exhibited antihyperglycemic properties attenuated hypercholesterolemia. OL-HT-OA, OL-HT-OC-OA cardioprotective, whereas only mitigated hyperglycemia. cardioprotection attributed apoptosis suppression, enhanced antioxidant upregulation enzymes. Additionally, it atherosclerotic plaque extent vivo. ameliorated cardiac, vascular endothelial function small-scale Conclusively, exerts vivo, remarkable clinically translatable high-risk

Language: Английский

Citations

5
Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management DOI Creative Commons

Yi Gao,

Di Zhou, Xue Bai

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: March 27, 2025

The survival rates of patients with hematological malignancies such as multiple myeloma have improved advances in cancer treatment. However, the risk cardiovascular disease associated novel therapeutic agents, including proteasome inhibitors (PIs), is becoming increasingly evident. PIs act on peptidases, leading to cell cycle arrest or apoptosis. Carfilzomib (CFZ), an intravenously administered irreversible PI, exhibits pronounced toxicity that characterized by heart failure, hypertension, arrhythmia, and ischemic (IHD). This review focuses CFZ, details its applications treating myeloma, presents potential mechanisms cardiotoxicity incidence cardiotoxic events, provides recommendations for evaluation management adverse cardiac events during early treatment this drug.

Language: Английский

Citations

0
Antifungal effects of Metformin against Candida albicans by autophagy regulation DOI
Xiao Zhao, Yang Wang, Qinqin Zhang

et al.

The Journal of Microbiology, Journal Year: 2025, Volume and Issue: 63(4), P. e2411008 - e2411008

Published: April 29, 2025

Language: Английский

Citations

0
Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma DOI Open Access
Marwa Tantawy, Taimour Langaee, Daqing Wang

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7795 - 7795

Published: July 16, 2024

This study investigates the association between circulating microRNA (miRNA) expression and cardiovascular adverse events (CVAE) in multiple myeloma (MM) patients treated with a carfilzomib (CFZ)-based regimen. A cohort of 60 MM from Prospective Observation Cardiac Safety Proteasome Inhibitor (PROTECT) was analyzed. Among these, 31 (51.6%) developed CVAE post-CFZ treatment. The Taqman OpenArray Human panels were used for miRNA profiling. We identified 13 differentially expressed miRNAs at baseline, higher expressions miR-125a-5p, miR-15a-5p, miR-18a-3p, miR-152-3p lower miR-140-3p who later compared to those free CVAE, adjusting age, gender, race, B-type natriuretic peptide levels. also three miRNAs, including miR-150-5p, that without post-treatment. Additionally, five responded differently CFZ treatment vs. non-CVAE patients, significantly elevated post-treatment miR-598, miR-152, miR-21, miR-323a patients. Pathway enrichment analysis highlighted involvement these diseases vascular processes. These findings suggest specific could serve as predictive biomarkers provide insights into underlying mechanisms CFZ-CVAE. Further investigation is warranted before can be applied clinical settings.

Language: Английский

Citations

0